Month: September 2026
-
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
Collaboration brings together complementary expertise and proprietary technologies to advance a next-generation radiopharmaceutical candidate with the potential to enhance tumor targeting. BOSTON, MA, September 9, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a research collaboration and…